Wiktoria Rejmak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wiktoria Rejmak has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Adam Lesner
Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland
2 shared publications - Katarzyna Bury
Laboratory of Molecular Biology, Intercollegiate Faculty of Biotechnology UG and MUG, University of Gdańsk, 80-307 Gdańsk, Poland
2 shared publications - Magdalena Wysocka
Faculty of Chemistry, University of Gdańsk
2 shared publications - Marta Bauer
Department of Analytical Chemistry, Faculty of Pharmacy, Medical University of Gdansk, 80-416 Gdansk, Poland
2 shared publications - Wojciech Kamysz
Department of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland
2 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1152
Building Blocks of 2,3-Diaminopropionic Acid Functionalized with an Oxa-Acid Spacer Shift the Functional Profile of Human Cathelicidin LL-37: Enhanced Enzymatic Stability and Selective Suppression of Neutrophil Degranulation
Background/Objectives: The human cathelicidin LL-37 (37 residues; net charge +6) couples broad-spectrum antimicrobial activity with immunomodulatory function, but rapid proteolysis and peptidylarginine deiminase (PAD)-mediated citrullination limit its therapeutic use. We aimed to enhance enzymatic stability and to test whether substitution with 2,3-diaminopropionic acid (Dap) building blocks bearing an oxa-acid spacer (DAPEG) shifts the functional profile of the LL-37 scaffold. Methods: Six LL-37 analogs were synthesized using Fmoc/tBu solid-phase peptide synthesis, replacing all five arginine, all six lysine, or three isoleucine residues with Dap bearing a one- or two-unit oxa-acid spacer. Identity, purity and secondary structure were assessed via mass spectrometry, ultra-performance liquid chromatography and circular dichroism. Proteolytic stability against human proteinase 3 (PR3), resistance to PAD2/PAD4 citrullination, DNA binding (dynamic light scattering), antibacterial activity, MTT cytotoxicity, and lipopolysaccharide-induced degranulation (PR3 and myeloperoxidase) in differentiated HL-60 cells were evaluated. Results: Proteolytic stability against PR3 increased 5.7-fold for the arginine-substituted Dap(GO1) analog, and both arginine analogs resisted PAD2- and PAD4-mediated citrullination, with Dap(GO2) being the most resistant. DNA binding was qualitatively retained, although dynamic light scattering showed weaker complex compaction for lysine analogs. All six analogs lost direct antibacterial activity and were non-cytotoxic at 1–10 µM. In differentiated HL-60 cells, the lysine-substituted Dap(O1) and Dap(O2) analogs suppressed lipopolysaccharide-induced secretion of both PR3 and myeloperoxidase from azurophilic granules, whereas isoleucine analogs were suppressed partially and arginine analogs behaved like native LL-37. Conclusions: The DAPEG framework shifts LL-37 from microbicidal toward degranulation-suppressive activity, providing a modular route to tune cathelicidin function. The intracellular mechanism (TLR4/FPR2 engagement, cytokine signaling) was not assayed.
- 24 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1152
Open AccessBuilding Blocks of 2,3-Diaminopropionic Acid Functionalized with an Oxa-Acid Spacer Shift the Functional Profile of Human Cathelicidin LL-37: Enhanced Enzymatic Stability and Selective Suppression of Neutrophil Degranulation
Background/Objectives: The human cathelicidin LL-37 (37 residues; net charge +6) couples broad-spectrum antimicrobial activity with immunomodulatory function, but rapid proteolysis and peptidylarginine deiminase (PAD)-mediated citrullination limit its therapeutic use. We aimed to enhance enzymatic stability and to test whether substitution with 2,3-diaminopropionic acid (Dap) building blocks bearing an oxa-acid spacer (DAPEG) shifts the functional profile of the LL-37 scaffold. Methods: Six LL-37 analogs were synthesized using Fmoc/tBu solid-phase peptide synthesis, replacing all five arginine, all six lysine, or three isoleucine residues with Dap bearing a one- or two-unit oxa-acid spacer. Identity, purity and secondary structure were assessed via mass spectrometry, ultra-performance liquid chromatography and circular dichroism. Proteolytic stability against human proteinase 3 (PR3), resistance to PAD2/PAD4 citrullination, DNA binding (dynamic light scattering), antibacterial activity, MTT cytotoxicity, and lipopolysaccharide-induced degranulation (PR3 and myeloperoxidase) in differentiated HL-60 cells were evaluated. Results: Proteolytic stability against PR3 increased 5.7-fold for the arginine-substituted Dap(GO1) analog, and both arginine analogs resisted PAD2- and PAD4-mediated citrullination, with Dap(GO2) being the most resistant. DNA binding was qualitatively retained, although dynamic light scattering showed weaker complex compaction for lysine analogs. All six analogs lost direct antibacterial activity and were non-cytotoxic at 1–10 µM. In differentiated HL-60 cells, the lysine-substituted Dap(O1) and Dap(O2) analogs suppressed lipopolysaccharide-induced secretion of both PR3 and myeloperoxidase from azurophilic granules, whereas isoleucine analogs were suppressed partially and arginine analogs behaved like native LL-37. Conclusions: The DAPEG framework shifts LL-37 from microbicidal toward degranulation-suppressive activity, providing a modular route to tune cathelicidin function. The intracellular mechanism (TLR4/FPR2 engagement, cytokine signaling) was not assayed.
- Open Access
- 1 June 2026
- Published by MDPI AG in Preprints.org
DAPEG-Modified Analogs of Human Cathelicidin LL-37: Enhanced Proteolytic Stability and Selective Modulation of Neutrophil Degranulation
The human cathelicidin LL-37 (37 amino acids; net charge +6) combines broad-spectrum antimicrobial activity with extensive immunomodulatory function, but its therapeutic exploitation is limited by rapid proteolytic degradation and post-translational inactivation through PAD-mediated citrullination of its arginine residues. We synthesized six analogs of LL-37 in which all five arginine residues (positions 7, 19, 23, 29, 34), all six lysine residues (positions 8, 10, 12, 15, 18, 25) or three isoleucine residues (positions 13, 20, 24) were replaced with the non-proteinogenic amino acid 2,3-diaminopropionic acid (Dap) functionalized on its side chain with either a one- or two-unit oxa-acid spacer (DAPEG building blocks). All compounds were obtained by Fmoc/tBu solid-phase peptide synthesis. Mass spectrometry, UPLC and circular dichroism confirmed identity, purity and partial retention of α-helical secondary structure. Proteolytic stability against human proteinase 3 was 5.7-fold increased for Dap(GO1)[7,19,23,29,34]LL-37 relative to native LL-37; both arginine-substituted analogs showed delayed citrullination by PAD2 and PAD4, with the two-oxa-unit Dap(GO2)[7,19,23,29,34]LL-37 conferring the greatest resistance. All analogs retained DNA binding by qualitative criteria, though DLS revealed reduced complex compaction for lysine-substituted analogs. All six DAPEG analogs lost the direct antibacterial activity of native LL-37 against reference Gram-positive and Gram-negative strains. None of the compounds was cytotoxic at 1–10 µM to HDFa, HB2, HL-60 or differentiated HL-60 cells. In differentiated HL-60 cells the lysine-substituted Dap(O1)[8,10,12,15,18,25]LL-37 and Dap(O2)[8,10,12,15,18,25]LL-37 analogs strongly suppressed LPS-induced secretion of both proteinase 3 and myeloperoxidase from azurophilic primary granules (~37-fold reduction of MPO at 1 h and 23–142-fold reduction at 24 h relative to LL-37 + LPS; all p < 0.001 by Sidak post-hoc) — a concordant two-marker signature of genuine inhibition of neutrophil degranulation. Isoleucine-substituted Dap(MO1)[13,20,24]LL-37 and Dap(MO2)[13,20,24]LL-37 analogs showed significant partial suppression of MPO secretion at both time points (p < 0.001 at 24 h); arginine-substituted analogs exhibited a biphasic phenotype, activating release at 1 h comparably to LL-37 but significantly reducing MPO at 24 h (p < 0.05). The DAPEG framework thus reprofiles the LL-37 scaffold from microbicidal toward selective immunomodulatory function, with the lysine-substituted analogs emerging as the most pharmacologically novel anti-inflammatory candidates.
- 1 June 2026
- Published by MDPI AG in Preprints.org
Open AccessDAPEG-Modified Analogs of Human Cathelicidin LL-37: Enhanced Proteolytic Stability and Selective Modulation of Neutrophil Degranulation
The human cathelicidin LL-37 (37 amino acids; net charge +6) combines broad-spectrum antimicrobial activity with extensive immunomodulatory function, but its therapeutic exploitation is limited by rapid proteolytic degradation and post-translational inactivation through PAD-mediated citrullination of its arginine residues. We synthesized six analogs of LL-37 in which all five arginine residues (positions 7, 19, 23, 29, 34), all six lysine residues (positions 8, 10, 12, 15, 18, 25) or three isoleucine residues (positions 13, 20, 24) were replaced with the non-proteinogenic amino acid 2,3-diaminopropionic acid (Dap) functionalized on its side chain with either a one- or two-unit oxa-acid spacer (DAPEG building blocks). All compounds were obtained by Fmoc/tBu solid-phase peptide synthesis. Mass spectrometry, UPLC and circular dichroism confirmed identity, purity and partial retention of α-helical secondary structure. Proteolytic stability against human proteinase 3 was 5.7-fold increased for Dap(GO1)[7,19,23,29,34]LL-37 relative to native LL-37; both arginine-substituted analogs showed delayed citrullination by PAD2 and PAD4, with the two-oxa-unit Dap(GO2)[7,19,23,29,34]LL-37 conferring the greatest resistance. All analogs retained DNA binding by qualitative criteria, though DLS revealed reduced complex compaction for lysine-substituted analogs. All six DAPEG analogs lost the direct antibacterial activity of native LL-37 against reference Gram-positive and Gram-negative strains. None of the compounds was cytotoxic at 1–10 µM to HDFa, HB2, HL-60 or differentiated HL-60 cells. In differentiated HL-60 cells the lysine-substituted Dap(O1)[8,10,12,15,18,25]LL-37 and Dap(O2)[8,10,12,15,18,25]LL-37 analogs strongly suppressed LPS-induced secretion of both proteinase 3 and myeloperoxidase from azurophilic primary granules (~37-fold reduction of MPO at 1 h and 23–142-fold reduction at 24 h relative to LL-37 + LPS; all p < 0.001 by Sidak post-hoc) — a concordant two-marker signature of genuine inhibition of neutrophil degranulation. Isoleucine-substituted Dap(MO1)[13,20,24]LL-37 and Dap(MO2)[13,20,24]LL-37 analogs showed significant partial suppression of MPO secretion at both time points (p < 0.001 at 24 h); arginine-substituted analogs exhibited a biphasic phenotype, activating release at 1 h comparably to LL-37 but significantly reducing MPO at 24 h (p < 0.05). The DAPEG framework thus reprofiles the LL-37 scaffold from microbicidal toward selective immunomodulatory function, with the lysine-substituted analogs emerging as the most pharmacologically novel anti-inflammatory candidates.